The Global Central Nervous System (CNS) biomarkers market is expected to grow at 10.4% CAGR during the forecast period 2016-2023. A biomarker is a biological feature that is used to measure the biological state, presence of diseases or the effects of treatment. It helps in understanding various chronic diseases, its effects on exposure to certain environmental conditions and also in identification of people who are at high risk of developing the same disease being diagnosed. The demand for CNS biomarker has increased with the development in proteomics, genomics and imaging system, which is a major drivers of the Global Central Nervous System Biomarkers Market. The global CNS biomarker market is witnessing a moderate to high growth in the recent years and is expected to continue so on in the near future. The central nervous system (CNS) biomarkers market is primarily driven by following factors:
- Development of proteomics, genomics and imaging system Funding from government and private players
- Increase in life style oriented diseases
- Increase in public-private partnership
- FDA approvals
- Technological advancement Innovation
- Global increase in healthcare expenditure
The key driver of the global CNS biomarkers market is increasing number of CVD patients. For example according to world health organization 8.8 million people died of cancer, in 2015. Also there were more than 191 million people suffering from chronic diseases in America in 2015. The increasing number of cancer patients and other cardiovascular diseases are fiving a rise to the need of CNS biomarkers. The major factors driving the CNS biomarker market are support from private players and government for increased research and development, development of genomics and imaging system, rapidly increasing geriatric population and increased public private partnerships. As per Administration for Community Living, population aged 65 and above is estimated to reach more than 80 million by 2050, which is twice of that estimated in 2012. This growth of geriatric population is leading to increased development of many diseases like Parkinson’s, Alzheimer’s and multiple sclerosis. As per the Aging Research Centre, approximately 24 million people are affected with Alzheimer’s disease globally. Governments are supporting and funding private and public laboratories to overcome this research and development program across the country. In addition, technological advancements and innovations, development of new applications areas, increasing lifestyle oriented diseases etc. are few factors which are likely to spur the demand of global CNS biomarker market.
Source: OBRC Analysis
The global central nervous system biomarkers market is segmented into type, application and end user. Type is further sub segmented into:
- Safety biomarkers,
- Efficacy biomarker
- Predictive biomarker
- Pharmacodynamic biomarker
- Prognostic biomarker
- Validation biomarker.
Application is further segmented into:
- Diagnostic development
- Drug discovery and development
- Personalized medicine
- Disease risk assessment
- Other
End-user is further segmented into:
- Hospitals
- Eye Clinics
- Diagnostic Centres
- Patients
The report scope is widely categorized on the basis of its application and type which include Safety biomarkers, efficacy biomarker, predictive biomarker, pharmacodynamic biomarker, prognostic biomarker and validation biomarker. Moreover, the market revenue estimates and forecast include hospitals, diagnostic centres, patients and eye-clinic.
Geographically, the global central nervous system biomarkers market is segmented into:
- North America (U.S. & Canada)
- Asia Pacific (China, India, Japan, RoAPAC)
- Europe (UK, France, Germany, RoE)
- Rest of World
Asia Pacific is anticipated to be one the fastest growing CNS markets in global CNS biomarkers market. The major reason for this high growth is wide customer base, improvement in healthcare infrastructure, purchasing power of buyers and increasing government initiatives. However at present, North America has the largest market share in global CNS biomarker marker because in the region healthcare infrastructure is more advanced than any other and also because of increasing geriatric population. For instance, according to the U.S. Census Bureau approximately 20% of the U.S. population is projected to be 65 years and above by 2030.
The global central nervous system biomarkers market is segmented on the basis of type, applications and end users. On the basis of type the market is segmented into safety biomarkers, efficacy biomarkers, predictive biomarkers, pharmacodynamic biomarkers, prognostic biomarkers and validation biomarkers. Application is sub segmented into diagnostic development, drug discovery and development, personalized medicine market, disease risk assessment market and other market. In the application segment personalized medicine market is expected to have a significant growth due to its increasing demand by patients. The end-user industry segments comprises of hospitals, eye clinics, diagnostic centres and patients.
The major market players of the global central nervous system biomarkers market are:
- ABIANT INC.,
- ACUMEN PHARMACEUTICALS INC.,
- ALSERES PHARMACEUTICALS INC.,
- APITOPE INTERNATIONAL,
- APOSENSE, AVACTA GROUP PLC
- BANYAN BIOMARKERS
- DIAGENIC ASA
- OTHERS
Detailed analysis of these companies provided in this report comprises of overview, SCOT analysis, product portfolio, strategic initiative and strategic analysis.
Expansions, mergers & acquisition and collaborations for product development are the key strategies adopted by the market players to sustain in the market also companies are applying for patents for any new product they develop. In January 2016, D Banyan Biomarkers entered into an agreement with Philips to develop and commercialize hand held blood test to evaluate and detect concussions. With this collaboration Banyan Biomarkers was able utilize its knowledge of bio molecules responsible for neurological injuries and take an advantage of Philips’ strength in handheld diagnostic and patient monitoring technologies.
Why to buy the report:
This report will:
- Provide you the business strategies adopted by market players such as partnership as in January 2016, D Banyan Biomarkers entered into an agreement with Philips.
- Provide in detail the different segments such as application and end-users which affect the global central nervous system biomarkers market.
- Provide you the patent analysis of the global central nervous system biomarkers market.
- Identify and understand the strengths, opportunities, challenges and threats of the central nervous system biomarkers market.
- Provide revenues of major players of global central nervous system biomarkers market.
- Provide you the various regulatory policies which affect the global central nervous system biomarkers market.
How we are different from others:
At Occams we provide an extensive portfolio which is comprehensive market analysis along with the market size, market share, and market segmentations. Our report on global central nervous system biomarkers market offers the longest chain of market segmentation based on application, type and end-users. The report tracks the major market trend in the global central nervous system biomarkers market. For each market segments covered in global central nervous system biomarkers market report we provide opportunity matrix, and DROC analysis, that enable the clear growth assessment across each market segment. The report discusses competitive landscape of the global central nervous system biomarkers market, with giving extensive strategy analysis of more than 15 companies. Moreover, the report discusses various models such as 360 degree analysis, See Saw analysis, and Porter five force models and so on. For the high level analysis in the report we provide a comparative analysis of historic and current year data.
Key findings of the global central nervous system (CNS) biomarkers market.
- North America accounted the largest revenue share in 2016.
- Application segment is expected to contribute highest growth of the CNS biomarkers market.
- Increase in healthcare spending and government favourable policies are creating huge opportunities for the global CNS biomarkers market.